Clinical trials: CMV Infection
Renal Transplant Infection
Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin
Renal transplant candidates who have CMV-specific, CD8+ T-cells, are CMV-seropositive and carry HLA-A1 and/ or HLA- A2 alleles have a high probability to maintain this type of immunity during the three first months after the…
- Trial name
- NCT03147183
- Testing
- Thymoglobulin
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Mothers, Cytomegalovirus Infections
Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy,
Reports of maternal seroconversion to CMV during pregnancy can be extremely stressful. This virus is little known to the general public and searching for information on the Internet quickly leads to a consultation of a site…
- Conditions
- Mothers, Cytomegalovirus Infections, Pregnancy Related
- Trial name
- PTSD CMV (NCT04658810)
- Testing
- Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Hospices Civils de Lyon
Colitis, HIV Infections
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS
To attempt to demonstrate the efficacy of ganciclovir (DHPG) treatment of cytomegalovirus (CMV) colitis in AIDS patients by evaluating both clinical and virologic parameters.
- Trial name
- NCT00002273
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Viraemia
Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
This study aims to determine: a) whether those patients with 'low level' viral load results (between 200 and 3,000 copies/ml) could be monitored as opposed to starting preemptive therapy with valganciclovir, ganciclovir and/or…
- Trial name
- NCT00947141
- Testing
- ganciclovir (start when CMV PCR >200copies / ml x2), Monitor (Treatment starts when CMV PCR >3,000 copies / ml), Stop treatment when 2 levels CMV PCR <3,000 copies / ml
- Where
- United Kingdom
- Volunteers
- 165 people
- Sponsor
- University College, London
Cytomegalovirus Infections, Heart Transplantation
A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age
This open label study will assess the pharmacokinetics and the safety and tolerability of Valcyte (valganciclovir) powder for oral solution in neonatal and infant heart transplant patients < 4 months of age.
- Trial name
- NCT01165580
- Testing
- valganciclovir [Valcyte]
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Infection
Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation
The purpose of this study is to evaluate the ability of the T-SPOT.CMV assay to determine immune competence against CMV infection in stem cell transplantation.
- Trial name
- REACT (NCT02470208)
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Oxford Immunotec
Cytomegalovirus (CMV)
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts.
- Trial name
- NCT05576805
- Where
- 15 sites in Austria, Belgium and 7 more
- Volunteers
- 159 people
- Sponsor
- Takeda
Cytomegalovirus Infection
Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
The objectives of this study were: 1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days of treatment. 2.
- Trial name
- NCT00730769
- Testing
- Single arm (ganciclovir and valganciclovir)
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Salvador Gil-Vernet
HIV I Infection
VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
This is a Phase 1a, first in human study in which healthy adult participants who are considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV) will receive two doses of VIR-1111 or placebo.
- Trial name
- NCT04725877
- Testing
- VIR-1111
- Where
- 3 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Encephalopathy, HIV Infections
A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.
To determine the safety and CSF penetration of combined ganciclovir and foscarnet treatment for presumed cytomegalovirus encephalitis or radiculomyelopathy.
- Conditions
- Encephalopathy, HIV Infections, Radiculitis
- Trial name
- NCT00000856
- Testing
- Foscarnet sodium, Ganciclovir
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Glioblastoma Multiforme, Cytomegalovirus Infection
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue.
- Trial name
- NCT00400322
- Testing
- Valganciclovir (Valcyte)
- Where
- 3 sites in Sweden
- Volunteers
- 42 people
- Sponsor
- Karolinska Institutet
Pneumonia, HIV/AIDS
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.
- Conditions
- Pneumonia, HIV/AIDS, Tuberculosis, Cytomegalovirus Infections
- Trial name
- EMPIRICAL (NCT03915366)
- Testing
- Valganciclovir Oral Solution [Valcyte], Tuberculostatic Agents
- Where
- 13 sites in Côte d’Ivoire, France and 9 more
- Volunteers
- 563 people
- Sponsor
- Hospital Universitario 12 de Octubre
Cytomegalovirus Infections
The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial
21 patients were randomised to receive instructions and coaching or no intervention on the use and intake of ganciclovir. Intake of medication was measured by an electronic pill box. The duration of the study was 100 days.
- Trial name
- NCT00566072
- Testing
- instructions and coaching
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Hospital, Ghent
Immune Senescence
Influence of Persistent CMV-infection on Immune Senescence
Recent studies indicate that persistent viral infections particularly with Cytomegalovirus (CMV) might have a negative impact on immune senescence (i.e. immunocompetence of elderly individuals).
- Trial name
- NCT00461695
- Testing
- Vaccination against TBEV (FSME Immun CC)
- Where
- Switzerland
- Volunteers
- 183 people
- Sponsor
- University of Zurich
Cytomegalovirus Infection, HSCT
Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients
Donor and recipient CMV-serostatus is one of the risk factor for CMV infection in solid organ transplantation. Recipients with IgG positive anti-CMV are classified as low-risk patients since it is considered that patients also…
- Trial name
- CYTHEMAT (NCT03210090)
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Infections, HIV Infections
Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
To provide ganciclovir on a compassionate use basis to immunocompromised patients with serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient population.
- Trial name
- NCT00002024
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
Viral Infection, Viral Reactivation
Third Party Viral Specific T-cells (VSTs)
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
- Conditions
- Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
- Trial name
- NCT02532452
- Testing
- Viral Specific VST Infusion
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Congenital Cytomegaloviral (CMV) Disease
CMV CTLs in Neonates With CMV Infection
Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened. All patients will receive treatment with valganciclovir or ganciclovir.
- Trial name
- NCT05564598
- Testing
- CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- New York Medical College
Non-HIV Patients With Pneumocystis Jiroveci Pneumonia
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)
PCP (Pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in immunocompromised patients including HIV-infected patients, transplant recipients, and immunosuppressant users.
- Trial name
- NCT02109887
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Asan Medical Center